Therapeutic Equivalence Evaluations Would Be Required For 505(b)(2) Drugs Under Senate User Fee Bill
Executive Summary
The Senate HELP Committee added a therapeutic equivalence provision to the draft measure it floated two weeks ago. The bill introduced in the Senate still does not include provisions on clinical trial diversity or 180-day exclusivity.
You may also be interested in...
505(b)(2)-Like Pathway For Biologics May Gain Renewed Interest With Senate User Fee Bill Pending
Draft legislative text would allow some biologics and biosimilars to rely on published literature or other information and avoid some clinical studies, but the wide FDA discretion also included could raise more questions.
Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances
FDA-crafted legislative text emerges that generic industry says could weaken the incentive, but so far no changes are in the draft House and Senate bills.
Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances
FDA-crafted legislative text emerges that generic industry says could weaken the incentive, but so far no changes are in the draft House and Senate bills.